Drug industry
Article Abstract:
Prices for drug stocks soared between Aug 1994 and Aug 1995, but the trend toward vertical and horizontal consolidation that is occurring in the industry will place a premium on investing in large multinational companies that offer a wide array of new medicines and have the wherewithal to fund research and development. Overall, drug stocks are no longer cheap and only a few have attractive rankings.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Myriad Genetics
Article Abstract:
The shares of Myriad Genetics, Inc. have wide price appreciation potential over the 2010-2012 timeframe. The Salt Lake City, Utah-based company develops tests to assess the risk of developing diseases and produces drugs for various diseases.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Amgen
Article Abstract:
The price appreciation potential of Amgen Inc. for the years 2010-2012 is discussed. The Thousand Oaks, California-based company develops and manufactures human therapeutic agents.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2007
User Contributions:
Comment about this article or add new information about this topic: